go to medicines.ie homepage
  • Home  |  
  • About  |  
  • Links  |  
  • Help
Font Size
Search for:  
select
select
  • SPCs and PILs
  • SPCs Only
  • PILs Only
  Advanced Search
  • What's
    New
      
  • Browse
    Medicines
      
  • Browse
    Active Ingredients
      
  • Browse
    Companies
      
  • Codes
    of Practice
      
  • Adverse
    Reaction Reporting

AstraZeneca Pharmaceuticals (Ireland) Ltd

AstraZeneca Pharmaceuticals (Ireland) Ltd
College Park House, 20 Nassau Street, Dublin 2,
Telephone: +353 1 609 7100
Fax: +353 1 679 6650
Medical Information e-mail: irelandproducts@astrazeneca.com
Summary of Product Characteristics last updated on medicines.ie: 05/07/2010
SPC Betaloc 50mg & 100mg Tablets

When a pharmaceutical company changes an SPC or PIL, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 05/07/2010 and displayed until Current
Reasons for adding or updating:
  • Change to product name
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.9 - Overdose
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   28-May-2010
Legal Category:   Product subject to medical prescription which may be renewed (B)

Free-text change information supplied by the pharmaceutical company



Section 1

Name change:

Betaloc 50mg Tablets

Betaloc 100mg Tablets

 

Section 2

Additional text:

Betaloc Tablets 50mg:

Each tablet contains Metoprolol tartrate 50mg

Each tablet contains 17.5mg lactose monohydrate

Betaloc Tablets 100mg:

Each tablet contains Metoprolol tartrate 100mg

Each tablet contains 35mg lactose monohydrate

 

Section 4.4

Additional text  2nd bullet point:

Acute initiation of high-dose metoprolol to patients undergoing non-cardiac surgery should be avoided, since it has been associated with bradycardia, hypotension and stroke including fatal outcome in patients with cardiovascular risk factors.  

 

Section 4.9

Change of text to whole of section:

The symptoms of overdose may include bradycardia, hypotension, acute cardiac insufficiency and bronchospasm.

General treatment should include: 

Close supervision, treatment in an intensive care ward, the use of gastric lavage, activated charcoal and a laxative to prevent absorption of any drug still present in the gastrointestinal tract, the use of plasma or plasma substitutes to treat hypotension and shock.

Excessive bradycardia can be countered with atropine 1-2 mg intravenously and/or a cardiac pacemaker.  If necessary, this may be followed by a bolus dose of glucagon 10 mg intravenously.  If required, this may be repeated or followed by an intravenous infusion of glucagon 1-10 mg/hour depending on response.  If no response to glucagon occurs or if glucagon is unavailable, a beta adrenoceptor stimulant such as dobutamine 2.5 to 10 micrograms/kg/minute by intravenous infusion may be given. 

Dobutamine, because of its positive inotropic effect could also be used to treat hypotension and acute cardiac insufficiency. It is likely that these doses would be inadequate to reverse the cardiac effects of beta blockade if a large overdose has been taken.  The dose of dobutamine should therefore be increased if necessary to achieve the required response according to the clinical condition of the patient.

Administration of calcium ions may also be considered. Bronchospasm can usually be reversed by bronchodilators.

 

Section 9

Renewal authorisation:

Betaloc 50mg: 26th May 2005

Betaloc 100mg: 29th May 2005

 

Section 10

New revision date of text: 28th May 2010

Updated on 04/04/2007 and displayed until 05/07/2010
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   12/2006
Legal Category:   prescription only

Free-text change information supplied by the pharmaceutical company

Section 4.4

New additional text – last paragraph.  Lactose warning.

 

This product contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose‑galactose malabsorption should not take this medicine.

 

Section 4.5

New additional text 3rd paragraph

Digitalis glycosides, in association with beta‑blockers, may increase atrioventricular conduction time and may induce bradycardia.

 

 

Section 4.8

In the adverse events for the cardiovascular system there is new additional text in “uncommon” with a reference.

 

Uncommon: Deterioration of heart failure symptoms, cardiogenic shock in patients with acute myocardial infarction*, first‑degree heart block, oedema, precordial pain.

*Excess frequency of 0.4% compared with placebo in a study of 46,000 patients with acute myocardial infarction where the frequency of cardiogenic shock was 2.3% in the metoprolol group and 1.9% in the placebo group in the subset of patients with low shock risk index. The shock risk index was based on the absolute risk of shock in each individual patient derived from age, sex, time delay, Killip class, blood pressure, heart rate, ECG abnormality, and prior history of hypertension. The patient group with low shock risk index corresponds to the patients in which metoprolol is recommended for use in acute myocardial infarction.

Section 4.9

Change of text in last paragraph

Current text:  The use of haemodialysis or haemoperfusion may be considered.

New text:  Betaloc cannot be effectively removed by haemodialysis.
 
Section 10
New date of revision - 4 December 2006
Updated on 24/11/2005 and displayed until 04/04/2007
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text
Updated on 23/06/2003 and displayed until 24/11/2005
Reasons for adding or updating:
  • New SPC for medicines.ie

Document Links

 
  View all medicines
from this company
View Document
Bookmark and Share

Active Ingredients

 
   Metoprolol Tartrate

Versions

 
05/07/2010 to Current
04/04/2007 to 05/07/2010
24/11/2005 to 04/04/2007
23/06/2003 to 24/11/2005
  • Terms & Conditions | 
  • Accessibility | 
  • Privacy Statement | 
  • Contact Us

Registered Address: Franklin House, 140 Pembroke Road, Dublin 4, Ireland
Registered Number: 254776
Tel: (353 1) 6603350 Fax: (353 1) 6686672 Email: info@ipha.ie

This website is certified by Health On the Net Foundation. Click to verify.

This site complies with the HONcode standard for trustworthy health information: verify here.

logo